Chemotherapy at the End of Life
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND AND OBJECTIVES: The use of chemotherapy at the end of life in advanced cancer patients has increased and end of life care has become increasingly aggressive. The aim of this study is to evaluate patients receiving chemotherapy in the last 3 months of life and the aggressiveness of end-of-life support of these patients. METHODS: All adult patients with solid tumors who received chemotherapy in their last 3 months of life and died in our hospital between January 2015 to June 2019 were included. Detailed information on chemotherapy and toxicity was collected in patient records. RESULTS: A total of 182 patients included. Median age was 58,9 years. The median survival from the docementation of metastatic disease was 9,98 months (0,95-64,3). Of these 182 patients, 95 (52%) were treated with chemotherapy in the last month of life and 52 (29%) in the last 2 weeks of life. The median number of days between the last administration of chemotherapy and patient death was 29 (0-90). A new chemotherapy regimen was started in the last 3 months of life in 102 patients (56%), in the last month of life in 43 patients (23,6%) and in the last 2 weeks in 23 patients (12.6%). DISCUSSION AND IMPLICATIONS: There are many patients who received chemotherapy in the last 3 months of their life and the rates of chemotherapy initiation during this period are well above ideal rates. Whether such care has positive effects on survival or quality of life is questionable and deserves additional investigation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Chemotherapy at the End of Life
- Date Crossref
- 06/08/2020
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Acıbadem University pays non établi dans la noticeUniversité ou école supérieure
-
Acıbadem Adana Hospital pays non établi dans la noticeÉtablissement de santé
-
Memorial Ankara Hospital pays non établi dans la noticeÉtablissement de santé
-
Acibadem University Vocational School of Health Services Radiotherapy pays non établi dans la noticeUniversité ou école supérieure
-
Acibadem Kayseri Hospital Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Ankara City Hospital General Surgery pays non établi dans la noticeÉtablissement de santé
Acıbadem University, Acıbadem Adana Hospital et Memorial Ankara Hospital, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.